| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.74(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
60,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$980,094 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
20,000 |
20,000 |
104,169 |
535,146 |
| Total Sell Value |
$460,127 |
$460,127 |
$2,968,197 |
$14,025,264 |
| Total People Sold |
2 |
2 |
4 |
8 |
| Total Sell Transactions |
2 |
2 |
12 |
30 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-08-05 |
4 |
AS |
$26.54 |
$27,283 |
D/D |
(1,028) |
70,032 |
|
-2% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-08-05 |
4 |
OE |
$5.43 |
$39 |
D/D |
5 |
71,060 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
10,702 |
71,055 |
|
- |
|
| Bhanji Muna |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
14,731 |
26,272 |
|
- |
|
| Epstein Robert S |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
14,731 |
23,451 |
|
- |
|
| Bishop John L |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
14,731 |
23,451 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
14,731 |
58,451 |
|
- |
|
| Holstein Jens |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
14,731 |
16,731 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
14,731 |
23,451 |
|
- |
|
| Holstein Jens |
Director |
– • – |
2022-06-14 |
4 |
S |
$16.27 |
$141,846 |
D/D |
(8,720) |
2,000 |
|
1% |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2022-06-10 |
4 |
B |
$16.33 |
$980,094 |
D/D |
60,000 |
159,761 |
2.81 |
-6% |
|
| Gordon Kevin K |
Director |
– • – |
2022-06-08 |
4 |
S |
$18.50 |
$277,502 |
D/D |
(15,000) |
8,720 |
|
9% |
|
| Gordon Kevin K |
Director |
– • – |
2022-06-08 |
4 |
OE |
$7.39 |
$110,850 |
D/D |
15,000 |
23,720 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-06-02 |
4 |
D |
$18.23 |
$18,376 |
D/D |
(1,008) |
60,353 |
|
- |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2022-06-02 |
4 |
D |
$18.23 |
$73,777 |
D/D |
(4,047) |
99,761 |
|
- |
|
| Anderson Bonnie H |
Executive Chairwoman |
• • – |
2022-06-02 |
4 |
D |
$18.23 |
$37,226 |
D/D |
(2,042) |
67,045 |
|
- |
|
| Anderson Bonnie H |
Executive Chairwoman |
• • – |
2022-05-01 |
4 |
D |
$20.47 |
$15,066 |
D/D |
(736) |
85,952 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-03-04 |
4/A |
AS |
$24.91 |
$578,535 |
D/D |
(23,033) |
61,361 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-03-04 |
4 |
AS |
$24.91 |
$577,783 |
D/D |
(23,003) |
61,391 |
|
3% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-03-04 |
4 |
OE |
$5.98 |
$26,354 |
D/D |
4,407 |
84,394 |
|
- |
|
| Chambers Rebecca |
Chief Financial Officer |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
20,728 |
54,728 |
|
- |
|
| Stapley Marc |
Chief Executive Officer |
• • – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
56,537 |
103,808 |
|
- |
|
| Anderson Bonnie H |
Executive Chairwoman |
• • – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
17,667 |
86,688 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
42,412 |
79,987 |
|
- |
|
| Nova Tina Susan |
President, CLIA U.S. |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
56,546 |
76,988 |
|
- |
|
524 Records found
|
|
Page 5 of 21 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.11 (0.53%) 
